GD2targeted
GD2-targeted refers to therapies directed against GD2, a disialoganglioside highly expressed on several solid tumors, especially neuroblastoma, some melanoma and sarcomas, with limited normal tissue expression outside the central nervous system and peripheral nerves. GD2 is a glycolipid antigen on the cell surface that has been pursued as an immunotherapy target because cancers often overexpress it while most normal tissues express it only at low levels.
The most established GD2-targeted therapy class is monoclonal antibodies, notably dinutuximab, which binds GD2 to trigger
Beyond naked antibodies, GD2-targeted strategies include chimeric antigen receptor (CAR) T cells directed at GD2, which
The term GD2-targeted encompasses ongoing research across neuroblastoma and other GD2-expressing cancers, including melanoma and sarcomas.